We have recently demonstrated that relaxin (RLX) acts as compensatory mediator in human heart failure. RLX inhibits the stimulation of endothelin-1, the most potent vasoconstrictor in heart failure. Upregulation of the endothelin type-B receptor (ET B ), which mediates endothelin-1 clearance and endothelial release of NO, represents a pivotal mode of RLX action. However, signal transduction and abundance of this phenomenon are unknown. Therefore, we investigated RLX-induced regulation of ET B in human umbilical vein endothelial, epithelial (HeLa), and vascular smooth muscle cells. In human umbilical vein endothelial cells and HeLa cells, but not in human vascular smooth muscle cells, RLX upregulated ET B expression and activated extracellular signal-regulated kinase-1/2 (ERK-1/2) and nuclear factor-B (NF-B), a transcription factor. PD-98059, a selective inhibitor of the mitogen-activated protein kinase kinase-1 (MEK-1)-ERK-1/2 pathway, abolished ERK-1/2 and NF-B activation and ET B upregulation. NF-B inhibition also prevented RLX-mediated ET B stimulation. In NF-B-luciferase reporter assays, we demonstrated complete inhibition of RLX-induced NF-B activation in cells transfected with dominant-negative Raf-1, MEK-1, or ERK-1/2 constructs, whereas dominant-negative Ras had no effect. In rat aorta and mesenteric artery, RLX pretreatment, in an ET B -dependent fashion, mitigated the maximum contractile response to endothelin-1, by 38Ϯ4% and 43Ϯ6%, and the endothelin-1 sensitivity (Ϫlog[EC 50 ]: aorta, 8.2Ϯ0.2 for vehicle versus 7.2Ϯ0.2 for RLX; mesenteric artery, 8.0Ϯ0.2 for vehicle versus 7.1Ϯ0.1 for RLX). RLX pretreatment augmented the dilator effect of the ET B agonist endothelin-3 by 100Ϯ8% and 133Ϯ13%. In conclusion, RLX stimulates endothelial and epithelial ET B via a Ras-independent Raf-1-MEK-1-ERK-1/2 pathway that activates NF-B. On vascular smooth muscle cells, ET B , a contributor to endothelin-mediated vasoconstriction, remains unaffected. This renders RLX a functional endothelin-1 antagonist. (Circ Res. 2003;92:32-40.)
T he insulin-related peptide relaxin (RLX) has long been regarded as a central hormone of human pregnancy that contributes to changes in connective tissue composition and to the regulation of implantation, myometrial activity, and labor. 1 On the other hand, we have recently found that RLX is constitutively expressed in human cardiovascular tissues and that myocardial gene expression of RLX is remarkably upregulated in human congestive heart failure. 2 What renders RLX particularly intriguing as a neurohumoral player and as a potential new therapeutic tool is its antagonism vis-à-vis endothelin-1 (ET-1), one of the most potent vasoconstrictors and a powerful mediator of salt retention, fibroproliferation, and myocardial remodeling. 3 We have shown that RLX induces upregulation of the endothelial endothelin type-B receptor (ET B ). 2 This receptor subtype stimulates endothelium-dependent vasodilation via NO and prostacyclin as well as clearance of ET-1. 3 Moreover, RLX, via this ET B mechanism, inhibits stimulated ET-1 release in endothelial cells and may cause the inverse correlation between circulating RLX and ET-1 in patients with end-stage heart failure. 2 Given the obvious importance of the RLX-induced ET B upregulation, it is crucial to know whether this phenomenon is restricted to endothelial cells only, because ET B is also found on epithelial and vascular smooth muscle cells (VSMCs). 3 Additionally, it would be of particular interest to investigate the ensuing signaling cascades. Because other members of the insulin family represent strong activators of extracellular signal-regulated kinases-1/2 (ERK-1/2) 4,5 and of nu-clear factor-B (NF-B, a transcription factor), 6 we hypothesized that ERK-1/2 and NF-B were involved in RLX actions.
In the present study, we investigated mechanisms, abundance, and functional consequences of RLX-dependent ET B upregulation in human endothelial, epithelial, and VSMCs.
Materials and Methods

Cell Culture
Primary human umbilical vein endothelial cells (HUVECs) were prepared according to standard procedures 7 and grown in MCDB-131 medium (GIBCO) supplemented with 1% L-glutamine, 100 U/mL penicillin, 100 g/mL streptomycin, 15% FCS, 1 ng/mL basic fibroblast growth factor, 0.1 ng/mL epidermal growth factor, 5 U/mL heparin, 1 g/mL hydrocortisone, and 0.4% endothelial cell growth supplement.
For primary human VSMCs (hVSMCs) prepared from mammary arteries, 8 we used DMEM (GIBCO) with 15% FCS, 100 U/mL penicillin, and 100 g/mL streptomycin.
HeLa cells and bovine aortic endothelial cells (BAECs) were obtained from American Type Culture Collection and grown in RPMI (GIBCO) supplemented with 10% FCS, 100 U/mL penicillin, and 100 g/mL streptomycin.
In all cells, FCS was lowered to 2% at 3 hours before the experiments. All cells were grown to subconfluence in a humidified 5% CO 2 atmosphere and used at passages 3 to 4. The primary cultures showed a purity of at least 95% as determined by immunostaining with anti-von Willebrand factor (HUVEC) and anti-smooth muscle actin (hVSMC) antibodies (Dako).
Western Blot Analysis
This analysis has been described previously. 2 For primary antibodies (dilution 1:2500), we used phospho-p44/42 (activated ERK-1/2), p44/42 (ERK-1/2), phospho-p38, and p38 mitogen-activated protein (MAP) kinase antibodies (Cell Signaling), ET B , and actin antibodies (Research Diagnostics).
Electrophoretic Mobility Shift Assays
Preparation of nuclear extracts and electrophoretic mobility shift assays were conducted as explained previously. 2 We used an H-2K oligo probe containing the NF-B recognition site (5Ј-GATCCCTGTGGAGATGGGGAATCCCCAGCCCTC-3Ј). We also performed supershift assays using monoclonal antibodies (Santa Cruz) against p65, c-Rel, p50, Rel-B, and p52.
RNA Analysis
RNA analysis has been described in detail. 2 Polymerase chain reaction (PCR) amplification of single-stranded cDNA was performed using primer pairs specific for human GAPDH (housekeeping gene) (5Ј primer, 5Ј-TGAAGGTCGGAGTCAACGGATTTGGT-3Ј; 3Ј primer, 5Ј-CATGTGGGCCATGAGGTCCACCAC-3Ј; Clontech), human ET B (5Ј primer, 5Ј-TTGGAGCTGAGATGTGTAAGC-3Ј; 3Ј primer, 5Ј-CAGTGAAGCCATGTTGATACC-3Ј), and human ET A (5Ј primer, 5Ј-CTGGCACTGGTTGGATGTGTA-3Ј; 3Ј primer, 5Ј-GCTTCAG-GAATGGCCAGGAT-3Ј). Subsequently, Southern blot hybridization was conducted for quantification of the amplified sequences using radioactively labeled oligonucleotides specific for human GAPDH, human ET B , and human ET A , as described. 2 Autoradiographs were quantified using ImageMaster 1D Prime software (Pharmacia Biotech).
Transient Transfections and Reporter Assays
HeLa cells and BAECs were seeded in tissue culture plates and grown to 70% confluence. Using cationic liposomes (Qiagen), we cotransfected cells with the NF-B-luciferase reporter gene construct (pGL2 vector) containing the NF-B recognition motif and the following dominant-negative (DN) expression constructs: DNRasN17 9 (pCMV5 vector), DNRaf-1 10 (pRSV), DNMEK-1 11 (pCEP4L; MEK-1 indicates mitogen-activated protein kinase kinase-1), DNERK-1 12 (pCEP4L), and DNERK-2 12 (pCEP4L). Transfections of 0.5 g cDNA each were carried out according to the manufacturer's instructions (Qiagen). After 6 hours of incubation at 37°C, cells were maintained in RPMI for 24 hours. Thereafter, experiments were performed, cells were harvested for measurement of transactivation activity, and luciferase activity was assayed in a ␤-counter, as recommended in the manufacturer's instructions (Promega). Data were normalized to transfection efficiency determined by cotransfection with the pSV-␤-galactosidase vector (Promega) using a spectrophotometric assay. The HeLa cells and BAECs exhibited no relevant endogenous ␤-galactosidase activity. The number of experiments was four in all cases.
Binding Assay
Membrane preparation and 125 I-ET-1 saturation binding were performed as previously described. 13 Nonspecific binding determined by coincubation with 100 nmol/L unlabeled ET-1 was Ͻ15% of total binding at all concentrations used. In endothelial cells, binding of 150 pmol/L 125 I-ET-1 was displaced by the ET B -selective antagonist A-192621 (Ϫlog[IC 50 ]ϭ9.0Ϯ0.04, nϭ3), whereas the ET A -selective antagonist ABT-627 showed no displacement up to 10 mol/L. This confirmed the commonly accepted notion that no relevant ET A population resided on these endothelial cells. 3, 14 
Isolated Vessels
Male Wistar rats (200 to 250 g body weight, Charles River Laboratories, Sulzfeld, Germany) were used for these experiments, which were approved by the institutional animal care and use committee. Thoracic aortas and renal and mesenteric arteries were cleaned, cut into strips, and mounted under 10-mN resting tension in an organ bath containing oxygenated Krebs-Henseleit buffer (37°C, pH 7.35 to 7.45). Isometric tension was recorded by means of a force transducer (Scientific Instruments). After a 120-minute equilibration period, preparations were exposed to a KCl (60 mmol/L) salt solution to assess maximum contractility. The presence of an intact endothelium was then verified by the occurrence of significant relaxations in response to acetylcholine (0.01 to 1 mol/L) after precontraction with phenylephrine (1 mol/L). We chose the following protocol (nϭ4 for each group): groups 1, 3, 5, 7, and 9 were treated with 1 nmol/L human RLX for 6 hours; groups 2, 4, 6, 8, and 10 received vehicle alone. Thereafter, the bathing medium was completely exchanged in all groups. In groups 1 and 2, we elicited cumulative dose-response curves to ET-1 (10 Ϫ11 to 10 Ϫ6 mol/L). In groups 3 and 4, these experiments were performed in the presence of the ET B -selective antagonist A-192621 15 (500 nmol/L). During the 6-hour incubation period, groups 5 and 6 and groups 7 and 8 additionally received 2-[2Ј-amino-3Ј-methoxyphenyl]-oxanaphtalen-4-one (PD-98059, 50 mol/L), a selective inhibitor of the MEK-1/ 2-ERK-1/2 pathway, 16 and cycloheximide (CHX, 10 g/mL), a protein synthesis inhibitor, respectively. Finally, groups 9 and 10 were mechanically endothelium-denuded before the experiments.
In distinct vessel preparations, an identical experimental protocol was performed to record cumulative dose-response curves to ET-3 (10 Ϫ12 to 10 Ϫ8 mol/L) after precontraction with phenylephrine (1 mol/L).
Tension data were normalized to the KCl or phenylephrine responses.
Reagents
Recombinant human RLX H2 was from Immundiagnostik. Angiotensin II, ET-1, ET-3, phorbol myristate acetate (PMA), PD-98059, tumor necrosis factor-␣ (TNF-␣), CHX, and N-␣-tosyl-Lphenylalanyl chloromethyl ketone (TPCK) were purchased from Sigma Chemical Co. A-192621 and ABT-627 were gifts from Abbott Laboratories (Abbott Park, Ill).
Statistical Analysis
Data are presented as meanϮSEM. A value of PϽ0.05 was regarded as significant. Densitometric and transfection data were analyzed using Kruskal-Wallis ANOVA on ranks. Dose-response curves were compared using a nonparametric ANOVA for repeated measures. A multiple-comparison procedure with Bonferroni-Holm adjustment of the P value was performed after global testing.
Results
ET B Expression, ERK-1/2, and NF-B Activation
We investigated the effect of RLX (0.1, 1, and 10 nmol/L) on ET B gene expression in the different cell types. RLX, in a concentration-dependent fashion reaching a plateau at 5 nmol/L, induced marked increases in ET B mRNA levels in HeLa cells and HUVECs, which were detectable as early as 2 hours after RLX and reached a plateau at 4 and 8 hours of exposure (data shown for 4 hours and 1 nmol/L RLX in Figure 1 and the Table) . In contrast, no change of ET B gene expression in response to RLX was found in hVSMCs. Control experiments showed ET B -stimulating effects of PMA (50 nmol/L) and angiotensin II (100 nmol/L) in HeLa cells and HUVECs and a decrease in ET B mRNA after exposure to angiotensin II in hVSMCs.
In accordance with the results obtained at the mRNA level, RLX also elevated ET B protein levels, in a CHX-dependent fashion, in HeLa cells and HUVECs, but not in hVSMCs ( Figure 1 and Table) .
Binding studies with 125 I-ET-1 using membranes from endothelial cells ( Figure 2 ) revealed a marked increase in the ET B receptor density B max after a 6-hour exposure of the cells to 1 nmol/L RLX (B max , 200Ϯ36 fmol/mg membrane protein for vehicle versus 611Ϯ56 fmol/mg membrane protein for RLX; nϭ3), whereas ET B binding affinity remained unchanged (K D , 126Ϯ18 pmol/L for vehicle versus 139Ϯ23 pmol/L for RLX).
In HeLa cells and HUVECs, RLX, like PMA and angiotensin II, was found to evoke activation of ERK-1/2 and enhanced DNA binding of the transcription factor NF-B at 45, 60, and 90 minutes after RLX exposure (data shown for 60 minutes in Figure 1 and in the Table) . In hVSMCs, PMA and angiotensin II, but not RLX, evoked substantial ERK-1/2 activation, whereas all three substances increased nuclear binding of NF-B.
In hVSMCs, but not in HeLa cells or HUVECs, RLX induced p38 activation at 45, 60, and 90 minutes after exposure (data shown for 45 minutes in Figure 1 ). RLX affected ET A gene expression in none of the studied cell types (not shown).
Supershift experiments in HeLa cells ( Figure 3 ) revealed substantial contribution of the p50 homodimer to the NF-B activation evoked by RLX and PMA.
Inhibition of ERK-1/2 and NF-B
Causal implication of the ERK-1/2 cascade in the RLX effect was confirmed by the finding that PD-98059 (50 mol/L), a selective inhibitor of the MEK-1/2-ERK-1/2 pathway, 16 completely suppressed translocation of NF-B and ET B upregulation in HeLa cells and HUVECs in response to RLX and angiotensin II ( Figure 4 and Table) . Effects of PMA on ERK and NF-B activation and on ET B expression were partially antagonized by PD-98059, with the NF-B response in HeLa cells being unaffected. Furthermore, TPCK (25 mol/L), which prevents NF-B activation by inhibiting degradation of different IB proteins, 17 abrogated not only the enhanced DNA binding of NF-B but also the increase in ET B gene expression in response to RLX. Thus, NF-B activation was critical to this RLX action. Similarly, the
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Reporter Assays
We first ensured that BAECs also exhibited RLX-induced upregulation of ET B protein, which was sensitive to ERK-1/2 inhibition by PD-98059 and NF-B inhibition by TPCK ( Figure 5 ). As shown in Figure 5 for HeLa cells and for BAECs, treatment with 1 nmol/L RLX for 45 minutes induced a markedly increased transactivation activity in control cells cotransfected with NF-B-luciferase reporter construct and empty vector. This RLX-related stimulation of NF-B activity was not affected in cells transfected with DNRas but was completely prevented in cells transiently expressing DNRaf-1, DNMEK-1, or DNERK-1 plus DNERK-2. We used TNF-␣ (10 ng/mL) as a control substance because its mode of NF-B activation is independent of the MEK-1-ERK-1/2 pathway. 18 Specificity of the effects evoked by the DN kinase constructs was confirmed by the fact that these transfections did not affect the TNF-␣-induced NF-B activation.
Functional Relevance of RLX-Induced ET B Stimulation
In all preparations (rat renal artery, thoracic aorta, and mesenteric artery), maximum tensions to KCl (mean obtained was 16Ϯ1.2ϫ10 3 N/m 2 in aortas, 15Ϯ1.3ϫ10 3 N/m 2 in mesenteric arteries, and 15Ϯ1.0ϫ10 3 N/m 2 in renal arteries) and acetylcholine-induced dilator responses in phenylephrine-precontracted preparations (Ϫ72Ϯ7% [aorta], Ϫ68Ϯ7% [mesenteric artery], and Ϫ72Ϯ6% [renal artery] of the phenylephrine response, determined at 1 mol/L acetylcholine) were comparable among groups 1 to 10. Likewise, responses to phenylephrine did not differ between groups 1 to 10. Figure 6 shows data obtained in aortic preparations that are representative of all three anatomic sites. Pretreatment with RLX (1 nmol/L) significantly mitigated the maximum contractile response to ET-1 by 38Ϯ4% (aorta), 43Ϯ6% (mesenteric artery), and 33Ϯ7% (renal artery) as well as the ET-1 sensitivity (Ϫlog [EC 50 ]: aorta, 8.2Ϯ0.2 for vehicle pretreatment versus 7.2Ϯ0.2 for RLX; mesenteric artery, 8.0Ϯ0.2 versus 7.1Ϯ0.1, respectively; and renal artery, 7.8Ϯ0.2 versus 7.2Ϯ0.1, respectively). Moreover, the effect of the ET Bselective agonist ET-3 was significantly augmented: by 100Ϯ8% (aorta), 133Ϯ13% (mesenteric artery), and 73Ϯ8% (renal artery) at maximum ET-3 concentration. In presence of the ET B -selective antagonist A-192621 (500 nmol/L), we found no difference between the RLX or vehicle-pretreated groups with respect to ET-1, and the ET-3 response was completely abolished. In endothelium-denuded strips, the ET responses of RLX-and vehicle-pretreated preparations were also indistinguishable. Furthermore, the effects of RLX could be abolished by treatment with the MEK-1/2-ERK-1/2 inhibitor PD-59098 (50 mol/L) or with the protein synthesis inhibitor CHX (10 g/mL).
Discussion
Known for many years as a hormone of human reproduction, 1 RLX has attracted more attention since the 1990s, when new studies revealed the remarkable pleiotropy of this mediator. 19 Meanwhile, implication of RLX in the neurohumoral response taking place in human congestive heart failure has been demonstrated. 2 In the present study, we offer first evidence that one crucial effect of RLX, ie, the upregulation of ET B receptors, (1) is obviously limited to endothelial and epithelial cells but is not present in VSMCs and (2) is mediated via Ras-independent activation of the Raf-1-MEK-1-ERK-1/2 pathway and the transcription factor NF-B(p50).
The latter conclusion is based on the facts that (1) both ERK-1/2 and NF-B are activated on RLX exposure in HeLa The finding that a cell type-dependent restriction of the RLX effect exists is of great relevance because ET B receptors fulfill distinct functions in endothelial and epithelial as opposed to VSMCs 3,14 : whereas endothelial/epithelial ET B expedites the release of vasodilatory and antifibroproliferative mediators (NO and prostacyclin) as well as clearance of ET-1 (thereby providing a physiological negative feedback within the ET-1 system), ET B on VSMCs contributes to the vasoconstrictor profile of ET-1. In human congestive heart failure, the ET B contribution to the overall vasoconstrictor effect of ET-1 is even increased. 20 In other words, the selective stimulation of endothelial/epithelial ET B expression renders RLX a functional ET-1 antagonist. Accordingly, we demonstrated, in three different vessels, an RLX-dependent augmentation of the ET B -mediated vasodilation along with a mitigation of the vasopressor effect of ET-1, which was clearly abolished after ET B blockade. The present results confirm the functional relevance of RLX-induced ET B upregulation, which is also supported by reports on a RLXinduced functionally ET B -dependent renal vasodilation in pregnant rats. 21 This functional evidence, ie, the fact that the net RLX effect is vasodilation, is particularly important because NF-B has also been reported to upregulate gene expression of the vasoconstrictors ET-1 and angiotensin II in certain cell types. 22 In a recent study, we have found that RLX is capable of inhibiting angiotensin II-mediated as well as pressure-induced ET-1 stimulation in pulmonary artery endothelial cells by an ET B -dependent mechanism 2 ; in detail, this RLX-related mitigation of ET-1 stimulation was attributed to massive ET B upregulation, which more than outweighed, by increased clearance, the slight to moderate elevation by RLX of ET-1 gene expression.
The question arises as to which mechanism(s) might underlie the different regulation by RLX of the ET B gene in endothelial/epithelial compared with smooth muscle cells. Our results favor the view that the activation by RLX of distinct kinase cascades, ie, ERK-1/2 in HeLa cells and HUVECs, but p38 in hVSMCs, accounts for this difference. Both kinase pathways may target NF-B, 23 but our data indicate the necessity of concerted NF-B and ERK-1/2 activation to stimulate ET B expression. This, in turn, suggests critical involvement of distinct kinases downstream from ERK-1/2, ie, p90 ribosomal S6 kinases, a point that must be addressed in future studies.
Our observation that the ERK-1/2-NF-B pathway is involved in RLX signaling represents one of the first investigations at this subreceptor level of RLX signal transduction. Until now, it was known that RLX links tyrosine phosphorylation to phosphodiesterase and adenylyl cyclase activity. 24 The present findings are in good accordance with a report by Zhang et al, 25 who, in human endometrial stromal cells and in the human monocytic cell line THP-1, also demonstrated RLX-induced ERK-1/2 activation. Most likely, all these effects are mediated via the recently identified RLX recep- tors 26 LGR 7 and LGR 8, which are G protein-coupled 7-transmembrane-domain receptors.
As to the functional relevance of RLX-induced vasodilation in humans, it has recently been shown that exogenous RLX represents a highly potent dilator in the human systemic circulation. 27, 28 Thus, the importance of RLX as a potential therapeutic tool in humans seems a matter of fact. Moreover, the pivotal role of RLX in the circulatory changes occurring during pregnancy has already been evidenced, at least in rats 21 : endogenous RLX mediates both the decrease in plasma osmolality and the increase in renal plasma flow. Whether endogenous RLX affects basal vessel tone in men and nonpregnant women remains to be investigated. It may be misleading to judge from the comparably low circulating RLX levels (Ͻ1 pmol/L in men and postmenopausal women, 2 Ϸ15 to 20 pmol/L in menstruating women, 29 and Ϸ150 pmol/L during pregnancy 30 ) because plasma levels are often poor indicators of locally effective concentrations.
In control experiments with PMA and angiotensin II, we reproduced several well-established findings: PMA as well as angiotensin II have repeatedly been reported to activate both ERK-1/2 and NF-B pathways. 23, 31, 32 On the other hand, PMA has also been found to stimulate p38 and c-Jun N-terminal kinase cascades and activator protein-1, a transcription factor. 23 Stimulation of p38 kinases by PMA and subsequent p38-mediated activation of NF-B may account for the fact that the ERK-1/2 inhibitor PD-98059 did not prevent (in HeLa cells) or only partially prevented (in HUVECs) the PMA-induced NF-B activation. The fact that PD-98059 inhibited PMA-related ERK-1/2 stimulation only partially in HeLa cells and HUVECs is most likely a dose-related problem because PMA is a very strong kinase inductor. Regarding the regulation of ET B , there are some reports in accordance with our finding of angiotensin IIinduced receptor downregulation in hVSMCs, 33 whereas the precise role of angiotensin II in the regulation of endothelial ET-1 receptors appears unknown from the literature. In the experiments shown in the present study, angiotensin II stimulated both epithelial and endothelial ET B via ERK-1/2 and NF-B.
As to the limitations of the present study, we mostly used tumorigenic epithelial cells (HeLa cells) and HUVECs, both of which are not necessarily representative of normal epithelial and endothelial cells. However, the results obtained in HUVECs could be confirmed in BAECs. In our vessel preparations, we further demonstrated complete endothelium dependence of the vasodilatory RLX effect. In addition, the existence of a RLX-ERK axis has been confirmed by others for human endometrial cells 25 and human uterine fibroblasts, 34 ie, for nontumorigenic cells.
We conclude that RLX promotes endothelial and epithelial, but not vascular smooth muscle, ET B via a Ras-independent Raf-1-MEK-1-ERK-1/2 kinase cascade that activates NF-B(p50). One of the consequences is significant mitigation of the vasopressor effect of ET-1. This finding may have an impact on future therapeutic strategies exploiting RLX in human heart failure or other states of disease.
